{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T14:18:18Z","timestamp":1783693098000,"version":"3.55.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s43441-026-00969-1","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:43:06Z","timestamp":1777138986000},"page":"934-937","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Why MASLD Trials Underselect the MENA Region Sites and What Sponsors and Regulators Must Change"],"prefix":"10.1007","volume":"60","author":[{"given":"Mohamed","family":"El-Kassas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M.","family":"AlNaamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Alswat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"5","key":"969_CR1","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","volume":"169","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Zelber-Sagi S, Lazarus JV, Wong VW, Yilmaz Y, et al. Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis. Gastroenterology. 2025;169(5):1017\u2013e10322. https:\/\/doi.org\/10.1053\/j.gastro.2025.02.044","journal-title":"Gastroenterology"},{"issue":"7","key":"969_CR2","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41575-025-01081-9","volume":"22","author":"M El-Kassas","year":"2025","unstructured":"El-Kassas M. Bridging the gap: increasing MENA representation in MASLD clinical trials. Nat Rev Gastroenterol Hepatol. 2025;22(7):457\u20138 https:\/\/doi.org\/10.1038\/s41575-025-01081-9","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"969_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/liv.15852","volume":"44","author":"ZM Younossi","year":"2024","unstructured":"YounossiZ M, Golabi P, Paik J, Owrangi S, Yilmaz Y, El-Kassas M, Alswat K, Alqahtani SA. Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa. Liver Int. 2024;44(4):1061\u201370. https:\/\/doi.org\/10.1111\/liv.15852","journal-title":"Liver Int"},{"issue":"10","key":"969_CR4","doi-asserted-by":"publisher","first-page":"e70342","DOI":"10.1111\/liv.70342","volume":"45","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Paik JM, Yilmaz Y, Kanat M, El-Kassas M, et al. Two-Decade Trends in MASLD and Its Complications in the Middle East and North Africa (2010\u20132021). Liver Int. 2025;45(10):e70342. https:\/\/doi.org\/10.1111\/liv.70342","journal-title":"Liver Int"},{"issue":"10","key":"969_CR5","first-page":"791","volume":"13","author":"M El-Kassas","year":"2025","unstructured":"El-Kassas M, AlNaamani KM, Khalifa R, Yilmaz Y, Labidi A, et al. Steatotic liver disease study foundation in Middle East and North Africa (SLMENA) collaborators. Mapping metabolic dysfunction-associated steatotic liver disease models of care across 17 Middle East and North Africa Countries: insights into guidelines, infrastructure, and referral systems. J Clin Transl Hepatol. 2025;13(10):791\u2013808","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"969_CR6","doi-asserted-by":"publisher","first-page":"e70108","DOI":"10.1111\/liv.70108","volume":"45","author":"M El-Kassas","year":"2025","unstructured":"El-Kassas M, Villota-Rivas M, Alswat KA, AlNaamani KM, Yilmaz Y, et al. Steatotic Steatotic liver disease study foundation in Middle East and North Africa (SLMENA) collaborators. metabolic dysfunction-associated steatotic liver disease in the MENA region: setting a research and action priority agenda. Liver Int. 2025;45(6):e70108. https:\/\/doi.org\/10.1111\/liv.70108","journal-title":"Liver Int"},{"issue":"6","key":"969_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","volume":"390","author":"SA Harrison","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, et al. A phase 3, randomized, controlled trial of resmetirom in nash with liver fibrosis. N Engl J Med. 2024;390(6):497\u2013509. https:\/\/doi.org\/10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"issue":"4","key":"969_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"issue":"12","key":"969_CR9","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, et al. NN9931-4296 investigators. a placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"issue":"1","key":"969_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1007\/s43441-020-00207-2","volume":"55","author":"J Lai","year":"2021","unstructured":"Lai J, Forney L, Brinton DL, Simpson KN. Drivers of start-up delays in global randomized clinical trials. Ther Innov Regul Sci. 2021;55(1):212\u201327. https:\/\/doi.org\/10.1007\/s43441-020-00207-2","journal-title":"Ther Innov Regul Sci"},{"issue":"4","key":"969_CR11","doi-asserted-by":"publisher","first-page":"e008012","DOI":"10.1136\/bmjgh-2021-008012","volume":"7","author":"J Miller","year":"2022","unstructured":"Miller J, Millum J. Ethical considerations in international clinical trial site selection. BMJ Glob Health. 2022;7(4):e008012. https:\/\/doi.org\/10.1136\/bmjgh-2021-008012","journal-title":"BMJ Glob Health"},{"issue":"2","key":"969_CR12","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.cct.2013.05.009","volume":"36","author":"SC Nair","year":"2013","unstructured":"Nair SC, Ibrahim H, Celentano DD. Clinical trials in the Middle East and North Africa (MENA) Region: grandstanding or grandeur? Contemp Clin Trials. 2013;36(2):704\u201310. https:\/\/doi.org\/10.1016\/j.cct.2013.05.009","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"969_CR13","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1017\/cts.2023.622","volume":"7","author":"CE Lawrence","year":"2023","unstructured":"Lawrence CE, Bruce VNM, Salberg LD, Edwards T, Morales C, et al. Quantitative assessment of the impact of standard agreement templates on multisite clinical trial start up time. J Clin Transl Sci. 2023;7(1):e204.","journal-title":"J Clin Transl Sci"},{"issue":"6","key":"969_CR14","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","volume":"73","author":"BA Davison","year":"2020","unstructured":"Davison BA, Harrison SA, Cotter G, Alkhouri N, Sanyal A, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020;73(6):1322\u201332. https:\/\/doi.org\/10.1016\/j.jhep.2020.06.025","journal-title":"J Hepatol"},{"issue":"3","key":"969_CR15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","volume":"29","author":"SA Harrison","year":"2023","unstructured":"Harrison SA, Allen AM, Dubourg J, Noureddin M, Alkhouri N. Challenges and opportunities in NASH drug development. Nat Med. 2023;29(3):562\u201373. https:\/\/doi.org\/10.1038\/s41591-023-02242-6","journal-title":"Nat Med"},{"issue":"1","key":"969_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/1740774517735536","volume":"15","author":"MD Neuman","year":"2018","unstructured":"Neuman MD, Gaskins LJ, Ziolek T. REGAIN Investigators. Time to institutional review board approval with local versus central review in a multicenter pragmatic trial. Clin Trials. 2018;15(1):107\u201311.","journal-title":"Clin Trials"},{"issue":"4","key":"969_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s40290-022-00432-0","volume":"36","author":"HM Hashan","year":"2022","unstructured":"Hashan HM, Al-Muteb SK, Alismail IA, Alsaleh ON, Alkherb ZM, et al. Evaluation of the performance of the gulf cooperation council centralised regulatory review process: strategies to improve product authorisation efficiency and quality. Pharmaceut Med. 2022;36(4):223\u201331. https:\/\/doi.org\/10.1007\/s40290-022-00432-0","journal-title":"Pharmaceut Med"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00969-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00969-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00969-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:49:43Z","timestamp":1783691383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-00969-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["969"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00969-1","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}